Clinical Trial Update: REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam [NA]

View source ↗

Summary

The REVIVE trial evaluating an in-vivo expandable foam to reduce exsanguination is currently recruiting for hemorrhagic shock and trauma indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Shock
• Traumatic Injury

Drugs mentioned

• REVIVE expandable foam

Snippet

Sponsor: Arsenal Medical, Inc. | Conditions: Hemorrhagic Shock, Trauma | NA | Status: RECRUITING